JY
GANX icon

Jeff Yass’s Gain Therapeutics GANX Stock Holding History

Jeff Yass’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.5K Buy
+35,700
New +$65.8K ﹤0.01% 12675
2026
Q1 		– Sell
-14,000
Closed -$45.1K – 13485
2025
Q4 		$45.1K Buy
+14,000
New +$37.4K ﹤0.01% 11786
2024
Q2 		– Sell
-13,500
Closed -$50.9K – 12430
2024
Q1 		$50.9K Buy
+13,500
New +$56K ﹤0.01% 11557
2023
Q3 		– Sell
-22,200
Closed -$99.5K – 12327
2023
Q2 		$99.5K Buy
+22,200
New +$108K ﹤0.01% 10953

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's GANX Position: Q2 2026 in Review

Jeff Yass reduced its Gain Therapeutics (GANX) stake by 82% in Q2 2026, selling an estimated $651K and leaving 78,206 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #12157.

Jeff Yass first reported a position in GANX in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.2M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Jeff Yass held 78,206 shares of Gain Therapeutics worth $159K as of Q2 2026.
  • Jeff Yass sold 353,061 Gain Therapeutics shares in Q2 2026, an estimated $651K.
  • Gain Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12157 holding.
  • Jeff Yass first reported a position in Gain Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Jeff Yass's Gain Therapeutics position peaked at $2.2M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.